Brief: MeiraGTx Says Treatment With Botaretigene Sparoparvovec Was Found To Have An Acceptable Safety Profile In Phase 1/2 Study

MeiraGTx Holdings

01/10/2022 15:04

Oct 1 (Reuters) - MeiraGTx Holdings PLC  MGTX.O :
    * LATE-BREAKING PHASE 1/2 DATA DEMONSTRATES SAFETY PROFILE
OF
INVESTIGATIONAL GENE THERAPY BOTARETIGENE SPAROPARVOVEC
(AAV-RPGR) AND SUSTAINED VISION IMPROVEMENT IN PATIENTS WITH
X-LINKED RETINITIS PIGMENTOSA (XLRP)
    * TREATMENT WITH BOTARETIGENE SPAROPARVOVEC WAS FOUND TO
HAVE AN
ACCEPTABLE SAFETY PROFILE IN PHASE 1/2 STUDY

Source text for Eikon:  ID:nGNX45PTNn 
Further company coverage:  MGTX.O 
 ((Reuters.Briefs@thomsonreuters.com;))